Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab in Pediatric Patients 1 to 5 Years of Age With CHAPLE Disease
NCT07142343Phase 4Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Feb 2030
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pozelimab in CD55-deficient protein-losing enteropathy (CHAPLE), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of Treatment-Emergent Adverse Event (TEAEs) at 52 weeks and Severity of TEAEs at 52 weeks. Started Mar 2026; status: recruiting.
02
Drugs
pozelimab
03
Conditions
CD55-deficient protein-losing enteropathy (CHAPLE)
Beyond the preview
Go deeper on NCT07142343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142343.